Clinical trials
Phase 2 Esophagitis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 3 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 2 |
| Takeda | 2 |
| University of Utah | 2 |
| Adare Pharmaceuticals, Inc. | 1 |
| Celldex Therapeutics | 1 |
| Dr. Falk Pharma GmbH | 1 |
| First Affiliated Hospital of Chengdu Medical College | 1 |
| Galera Therapeutics, Inc. | 1 |
| MedImmune LLC | 1 |
| Medical College of Wisconsin | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Esophagitis | 22 |
| Eosinophilic Esophagitis | 9 |
| Esophageal Diseases | 4 |
| Deglutition Disorders | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Digestive System Diseases | 2 |
| Esophageal Neoplasms | 2 |
| Gastroesophageal Reflux | 2 |
| Gastrointestinal Diseases | 2 |
| Lung Neoplasms | 2 |
Trials
Showing 51 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.